Buy now: price is pulling back pre-market (~214, -1.83%) into a strong uptrend, offering a better entry than the prior ~218 area.
Trend/model tilt is constructive beyond the next day: pattern stats indicate ~70% chance of a small next-day dip (-0.41%), but stronger odds of gains over the next week/month (+10.67% / +12.22%).
Wall Street is broadly bullish with multiple recent upgrades/price-target hikes into the $233–$245 range, supporting continued momentum.
MACD: Histogram +0.639 and expanding, reinforcing positive momentum.
RSI (6): 70.13 (hot/near-overbought); suggests momentum is strong but upside may come with short pullbacks.
Key levels:
Pivot/support: 212.92 (current pre-market ~214 is just above)
Resistance: 218.26 (R1) then 221.57 (R2)
Lower supports: 207.57 (S1) then 204.26 (S2)
Read-through: Technically favorable to buy dips near the pivot; a reclaim/hold above ~218 improves odds of a push toward ~221.6.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Skews bullish—OI put/call 0.75 and especially volume put/call 0.26 indicate call-side dominance.
Volatility: 30D IV 24.59 vs historical vol 43.35; IV rank ~23.6 / percentile 46 implies options are not priced for extreme moves.
Activity: Total volume 1,822 with call volume 1,451 vs put volume 371; volume is ~78% of 30D average, so not a “crowded” options chase today.
Positioning: Total OI 48,194 with more calls (27,486) than puts (20,708), consistent with a bullish bias.
Technical Summary
Sell
2
Buy
9
Positive Catalysts
Analyst momentum: Multiple recent upgrades/price target raises (Citi upgrade; Morgan Stanley/TD Cowen/Barclays bullish), reinforcing the “drug distribution strength/specialty build-out” narrative.
Sector tailwind: News flow highlights ongoing strength in healthcare distribution and specialty pharma positioning (peer commentary and raised targets).
Upcoming earnings catalyst: Next report is QDEC 2025 earnings on 2026-02-05 (pre-market); bullish positioning and strong trend often benefit from event-driven attention if results/guide align.
Neutral/Negative Catalysts
Margin pressure: Latest quarter showed gross margin down YoY, a potential talking point into earnings.
Wall Street pros: Stronger specialty positioning, resilient core distribution, and a favorable industry backdrop with scope for multiple expansion.
Wall Street cons: Ongoing concerns around parts of the GMPD businesses and margin sensitivity (distribution is scale-driven and pricing/mix can matter).
Influential trading check:
Hedge funds: Neutral (no significant trend last quarter)
Insiders: Neutral (no significant trend last month)
Congress trading (90 days): No data/none reported
People Also Watch
Wall Street analysts forecast CAH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAH is 225.18 USD with a low forecast of 209 USD and a high forecast of 244 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast CAH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAH is 225.18 USD with a low forecast of 209 USD and a high forecast of 244 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 227.180
Low
209
Averages
225.18
High
244
Current: 227.180
Low
209
Averages
225.18
High
244
Mizuho
Steven Valiquette
maintain
$222 -> $235
AI Analysis
2026-02-06
New
Reason
Mizuho
Steven Valiquette
Price Target
$222 -> $235
AI Analysis
2026-02-06
New
maintain
Reason
Mizuho analyst Steven Valiquette raised the firm's price target on Cardinal Health to $235 from $222 and keeps an Outperform rating on the shares. The firm updated the company's model post the earnings report.
Evercore ISI
Outperform
maintain
$250 -> $260
2026-02-06
New
Reason
Evercore ISI
Price Target
$250 -> $260
2026-02-06
New
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Cardinal Health to $260 from $250 and keeps an Outperform rating on the shares. The firm sees positive progress stemming from consistent execution, the analyst tells investors in a post-earnings note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CAH
